News
Enhertu is already approved as a second-line or later therapy for HER2-positive breast cancer based on the results of the ...
The data show that a regimen based on Trodelvy and PD-1 inhibitor Keytruda (pembrolizumab) was better than Keytruda plus ...
Sanofi and Regeneron's Dupixent (dupilumab) has been approved by the FDA for the treatment of chronic spontaneous urticaria ...
March was a light month across the board for hires news, but the digital and supplier sectors in biopharma saw a spat of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results